^
    Back
    Association details:
    Biomarker:CDKN2A deletion
    Cancer:Melanoma
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2019
    Title:

    Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

    Excerpt:
    Monotherapy with P demonstrated evidence of anti-tumor activity in heavily pre-treated NSCLC pts with CDKN2A loss or mutation.
    DOI:
    10.1200/JCO.2019.37.15_suppl.9041
    Trial ID:
    TAPUR
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Pigment Cell Melanoma Res
    Title:

    Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

    Excerpt:
    In 47 melanoma cell lines homozygous loss, methylation or mutation of CDKN2A gene or loss of protein (p16(INK) (4A) ) predicted sensitivity to the CDK4/6 inhibitor PD0332991, while RB1 loss predicted resistance.
    DOI:
    10.1111/pcmr.12228